Second Line Therapy for Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going?

  • Christina Brus Yale Cancer Center, Yale University School of Medicine. New Haven, CT, USA
  • Muhammad Wasif Saif Yale Cancer Center, Yale University School of Medicine. New Haven, CT, USA
Keywords: 130-nm albumin-bound paclitaxel, capecitabine, gemcitabine-oxaliplatin regimen, Pancreatic Neoplasms

Abstract

Most patients with adenocarcinoma of the pancreas present with locally advanced or metastatic disease. Although single agent gemcitabine is widely accepted as first-line therapy, there is no current standard of care for gemcitabine-refractory patients. Common second-line chemotherapy regimens included oxaliplatin and 5-FU/leucovorin (OFF), gemcitabine and oxaliplatin (GEMOX), oxaliplatin and capecitabine (XELOX), and irinotecan-oxaliplatin. At the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, several new second-line chemotherapy regimens were presented, including gemcitabine and oxaliplatin with imatinib, single agent nab-paclitaxel, and the combination of high-dose capecitabine with oxaliplatin and sorafenib. These abstracts provide exciting new directions for the treatment of gemcitabine-refractory advanced pancreatic cancer.

Image: Yale Cancer Center, Yale University School of Medicine. New Haven, CT, USA

Downloads

Download data is not yet available.

References

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385]

Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156]

Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaneret I, et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 2005; 23(16 Suppl):4031.

Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26(15 Suppl):4508.

Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94:481-5. [PMID 16434988]

Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Oncology 2009; 76:333-7. [PMID 19307739]

Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67:93-7. [PMID 15539911]

Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101:1658-63. [PMID 19826418]

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008: 113:2046-52. [PMID 18756532]

Oettle H, Arnold D, Esser M, Huhn D, Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11:635-8. [PMID 11081455]

Starling N, Hawkes EA, Chau I, Watkins DJ, Thomas J, Webb J, et al. A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC). J Clin Oncol 2010; 28(15 Suppl):4155.

Lubner SJ, Schelman WR, Mulkerin D, Holen KD, Seo S, LoConte NK. Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer. J Clin Oncol 2010; 28(15 Suppl):4143.

Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007; 25:319-25. [PMID 17235047]

Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 2009; 27(15 Suppl):4525.

Hosein PJ, Lopes GD Jr., Gomez CM, Pastorini VH, Macintyre J, Easey M, et al. A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy. J Clin Oncol 2010; 28(15 Suppl):4120.

Yale Cancer Center, Yale University School of Medicine. New Haven, CT, USA
Published
2010-07-05
How to Cite
BrusC., & SaifM. (2010). Second Line Therapy for Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going?. JOP. Journal of the Pancreas, 11(4), 321-323. https://doi.org/10.6092/1590-8577/3613
Section
Highlights from the “2010 ASCO Annual Meeting”. Chicago, IL, USA. June 4-8, 2010

Most read articles by the same author(s)